Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Blay, J Y ^a,c   Le Cesne, A ^b,c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE COMPARISON; DRUG RESPONSE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM STAGING; PIPERAZINES; PYRIMIDINES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 39349091963     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm024     Document Type: Article

References (10)

1. Kindblom LG, Meis KindBlom J, Bumming P et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): A population based study of 600 cases. Ann Oncol 2003; 13: 157.
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-3825.
3. Demetri GD, Benjamin RS, Blanke C et al. Optimal management of patients with Gastrointesinal stromal tumors. Expansion and update of NCCN Clinical Practice Guidelines. J Natl Compr Cancer Netw 2004; 2 (Suppl 1).
4. Blay JY, Bonvalot S, Casali P et al. GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578.
5. Fletcher CDM, Berman JJ, Corless CL et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.
6. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
7. Verweij J, Casali P, Zalcberg J et al. Improved progression free survival in gastrointestinal stromal tumors with high dose Imatinib. Results of a randomized phase III study of the EORTC, ISG and AGITG. Lancet 2004; 364: 1127-1134.
8. Rankin C, von Mehren M, Blanke C et al. Continued prolongation of survival by imatinib in patients with metastatic GIST. Update of Results from North American Intergroup Phase III Study S0033. Proc Am Soc Clin Oncol 2004; 23: 815 (Abstr 9005).
9. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Results of mutation analysis in 377 patients entered into a randomized study. Eur J Cancer 2006; 42 (8): 1093-1103.
10. Blay JY, Berthaud P, Perol D et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 2004 (Abstr 9006).